Lung cell transplantation for the treatment of pulmonary fibrosis
Lung-forming progenitor cell therapy without preconditioning effectively treats pulmonary fibrosis by enabling robust engraftment and regeneration, addressing the limitations of current therapies.
JP2026504282APending Publication Date: 2026-02-04BOARD OF RGT THE UNIV OF TEXAS SYST
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025540004
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-01-25
- Filing Date
- 2024-01-24
- Publication Date
- 2026-02-04
AI Technical Summary
Technical Problem
Current lung transplantation therapies for pulmonary fibrosis require preconditioning regimens that are intensive and not suitable for all patients, limiting their accessibility and effectiveness.
Method used
Administering lung-forming progenitor cells without preconditioning to subjects with moderate to advanced pulmonary fibrosis, utilizing cell suspensions that express specific markers and potentially combining with immunosuppressive therapies.
Benefits of technology
Enables robust engraftment and regeneration of donor-derived cells, reducing fibrosis and improving lung function without the need for preconditioning, expanding treatment accessibility.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein is a lung-forming progenitor cell therapy that does not require preconditioning treatment. Administration of the progenitor cells can replace or replenish a population of host-derived patch-forming cells to reverse or suppress fibrosis, promote healing, and improve lung function. Also disclosed herein are methods for monitoring fibrosis and determining whether a subject is susceptible to progenitor cell therapy.
Need to check novelty before this filing date? Find Prior Art